Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

Objectives Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother‐to‐child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the...

Full description

Saved in:

Bibliographic Details
Published in:	HIV medicine Vol. 15; no. 1; pp. 50 - 56
Main Authors:	Zorrilla, CD, Wright, R, Osiyemi, OO, Yasin, S, Baugh, B, Brown, K, Coate, B, Verboven, P, Mrus, J, Falcon, R, Kakuda, TN
Format:	Journal Article
Language:	English
Published:	England BlackWell Publishing Ltd 01-01-2014
Subjects:	Adolescent Adult Darunavir Drug Administration Schedule Female Fetal Blood - chemistry HIV HIV Infections - drug therapy HIV Infections - metabolism HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - pharmacokinetics HIV-1 Human immunodeficiency virus 1 Humans Infectious Disease Transmission, Vertical - prevention & control pharmacokinetics Pregnancy Pregnancy Complications, Infectious - drug therapy Pregnancy Complications, Infectious - metabolism Pregnancy Outcome ritonavir Ritonavir - administration & dosage Ritonavir - pharmacokinetics Short Communications Sulfonamides - administration & dosage Sulfonamides - pharmacokinetics Young Adult pharmacokinetics darunavir HIV pregnancy ritonavir
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!